LGD-6972-5 mg
L6972-04
Phase 2 small_molecule completed
Quick answer
LGD-6972-5 mg for Type 2 Diabetes Mellitus is a Phase 2 program (small_molecule) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LIGAND PHARMACEUTICALS INC
- Indication
- Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed